BioBlog

Happy Independence Day to all of our American readers! In this week’s Innovation Partners BioBlog, we take a look at several updates from the pharmaceutical world. AstraZeneca is the first company to participate in a new FDA program to disclose all patient-reported symptoms during drug trials. The

Breakthroughs announced this week at the AACR Virtual Meeting show that the pace of cancer diagnosis, testing, and treatment hasn't slowed despite the worldwide pandemic. Clinical trials of a new personalized cancer vaccine show promise, while researchers appear to have developed a blood test that

This week’s Innovation Partners BioBlog focuses on oncology updates. NICE backs funding for Roche’s lung cancer drug, Rozlytrek, after the company offers discounts. New personalized oncology treatments may be available based on patients’ genetic profiles thanks to a partnership between MD Anderson

In this week’s edition of the Innovation Partners BioBlog, we look at two stories related to pharmaceutical giant AstraZeneca. AstraZeneca has identified two potential antibodies against COVID-19 and expect to move them into the clinic by August. However, this means that AstraZeneca’s merger with

ASCO’s conference, the 2020 Community Oncology Alliance Annual Conference, and other meets continue apace despite the COVID-19 pandemic. Conferences that have moved online are now presenting their findings virtually. Among them are a leadership panel addressing issues in cancer care, ASCO’s annual

In this weeks' Innovation Partners BioBlog, experts share opinions on how the healthcare industry will change after the first wave of the COVID-19 crisis passes. CVS plans to open more testing centers and hopefully process 1.5 million tests per month, depending on laboratories and supplies. And

This week, several advances in the oncology world brought new hope to patients suffering from lung and pancreatic cancer. Roche’s Tecentriq gained new first-line lung cancer use while a Roswell Park Team developed a two-pronged approach to pancreatic cancer that offers promise. Oncologists received

A two-combo cancer therapy has received FDA authorization for clinical researchers at a cancer center to begin a safety and effectiveness study. New data may have identified a genetic risk for lung cancer. The Trump Administration earmarked more money for states to conduct additional COVID-19